BRIACELL THERAPEUTICS CORP. Deferred Offering Costs
BRIACELL THERAPEUTICS CORP. (BCTX) had Deferred Offering Costs of $3.43 million as of 2021-07-31, per its 10-K filed 2022-10-28.
Discontinued › Balance Sheet › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2022-10-28
- 2021-07-31: Deferred Offering Costs $3.43M.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-07-31 | $3.43M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |